ATE483473T1 - Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs - Google Patents

Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs

Info

Publication number
ATE483473T1
ATE483473T1 AT04450149T AT04450149T ATE483473T1 AT E483473 T1 ATE483473 T1 AT E483473T1 AT 04450149 T AT04450149 T AT 04450149T AT 04450149 T AT04450149 T AT 04450149T AT E483473 T1 ATE483473 T1 AT E483473T1
Authority
AT
Austria
Prior art keywords
antibodies
against cancer
low dose
vaccinate against
antibody
Prior art date
Application number
AT04450149T
Other languages
English (en)
Inventor
Hans Loibner
Gottfried Himmler
Manfred Schuster
Original Assignee
Altropus Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE483473(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altropus Gmbh filed Critical Altropus Gmbh
Application granted granted Critical
Publication of ATE483473T1 publication Critical patent/ATE483473T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04450149T 2004-07-20 2004-07-20 Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs ATE483473T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04450149A EP1618890B1 (de) 2004-07-20 2004-07-20 Verwendung von Antikörpern in einer sehr geringen Dosis zur Impfung gegen Krebs

Publications (1)

Publication Number Publication Date
ATE483473T1 true ATE483473T1 (de) 2010-10-15

Family

ID=34933149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04450149T ATE483473T1 (de) 2004-07-20 2004-07-20 Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs

Country Status (4)

Country Link
US (1) US20060018901A1 (de)
EP (1) EP1618890B1 (de)
AT (1) ATE483473T1 (de)
DE (1) DE602004029455D1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
WO2011063133A1 (en) 2009-11-18 2011-05-26 Auburn University LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE
JP6216301B2 (ja) 2014-09-19 2017-10-18 ミネベアミツミ株式会社 照明装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226150B1 (en) * 1999-01-13 2008-05-28 Igeneon Krebs Immuntherapie Use of antibodies for anticancer vaccination

Also Published As

Publication number Publication date
US20060018901A1 (en) 2006-01-26
DE602004029455D1 (de) 2010-11-18
EP1618890A1 (de) 2006-01-25
EP1618890B1 (de) 2010-10-06

Similar Documents

Publication Publication Date Title
ATE473760T1 (de) Monoklonale antikörper gegen den hepatozyten- wachstumsfaktor
FI1897548T4 (fi) T-solujen säätely
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
DE50000243D1 (de) Verwendung von antikörpern zur vakzinierung gegen krebs
NZ527283A (en) Modified antibodies and methods of use
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
DE60138641D1 (de) Herstellung von mikrokügelchen
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
NZ600143A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
ATE521366T1 (de) Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
ATE528319T1 (de) Krebsbehandlung mit anti-il-1-antikörpern
ATE453328T1 (de) Verbesserte formulierung zur bereitstellung eines magensaftresitenten beschichtungsmaterials
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
NO20012135D0 (no) Forsterkede vaksiner
ATE483473T1 (de) Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
EP1979010A4 (de) Biologische wundversorgung und herstellungsverfahren dafür
EP1870456A4 (de) Verfahren zur herstellung eines gegen ein zellmembranoberflächenantigenepitop gerichteten antikörpers und testverfahren
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
DE112005001260A5 (de) Antigen des PM-2 Antikörpers und dessen Verwendung
ATE526035T1 (de) Tollwut-impfstoff
TR201902670T4 (tr) Anti-5t4 antikorları ve bunların kullanımları.
CY1115868T1 (el) Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1618890

Country of ref document: EP